Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBITDA (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of EBITDA readings, the most recent being $63.7 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 12.51% to $63.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $221.3 million, a 12.17% increase, with the full-year FY2025 number at $214.3 million, up 30.7% from a year prior.
  • EBITDA hit $63.7 million in Q1 2026 for Catalyst Pharmaceuticals, up from $52.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $63.7 million in Q1 2026 to a low of -$30.8 million in Q3 2023.
  • Median EBITDA over the past 5 years was $37.8 million (2023), compared with a mean of $35.1 million.
  • Biggest five-year swings in EBITDA: tumbled 234.3% in 2023 and later skyrocketed 242.63% in 2024.
  • Catalyst Pharmaceuticals' EBITDA stood at $25.5 million in 2022, then surged by 36.84% to $34.8 million in 2023, then surged by 60.72% to $56.0 million in 2024, then decreased by 5.9% to $52.7 million in 2025, then rose by 20.96% to $63.7 million in 2026.
  • The last three reported values for EBITDA were $63.7 million (Q1 2026), $52.7 million (Q4 2025), and $52.8 million (Q3 2025) per Business Quant data.